Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

NCT02111564 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT02111564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02111564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 3
Overall status
Completed
Start date
January 7, 2014
Completion date
May 3, 2018
Enrollment
12,024 (actual)
Sites
593

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, infectious diseases, respiratory insufficiency, rheumatic diseases, stroke acute